Kymera Therapeutics

KYMR

Market cap $4.88B

KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December 2025 WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis (AD).

WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics, Inc. ( KYMR ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera Therapeutics.

Kymera Therapeutics, Inc. ( KYMR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Marc Frahm - TD Cowen, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Sudan Loganathan - Stephens Inc., Research Division Brandon Frith - Wolfe Research, LLC Srikripa Devarakonda - Truist Securities, Inc., Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Jeet Mukherjee - BTIG, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Joseph Catanzaro - Mizuho Securities USA LLC, Research Division Presentation Operator Good day, everyone.

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago.

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies

Kymera Therapeutics (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.